[go: up one dir, main page]

AR095019A1 - Derivados de amatoxina - Google Patents

Derivados de amatoxina

Info

Publication number
AR095019A1
AR095019A1 ARP140100717A ARP140100717A AR095019A1 AR 095019 A1 AR095019 A1 AR 095019A1 AR P140100717 A ARP140100717 A AR P140100717A AR P140100717 A ARP140100717 A AR P140100717A AR 095019 A1 AR095019 A1 AR 095019A1
Authority
AR
Argentina
Prior art keywords
target
residue
amatoxin
heterocycloalkylene
amylene
Prior art date
Application number
ARP140100717A
Other languages
English (en)
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Publication of AR095019A1 publication Critical patent/AR095019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Conjugados de una amatoxina y a un resto de unión a una diana, por ej. un anticuerpo, conectado por ciertas ligaciones, los cuales son útiles en el tratamiento de cáncer y de otros trastornos y enfermedades. En un aspecto adicional se proveen composiciones farmacéuticas que comprenden ese tipo de conjugados y la utilización de estos en la terapia tumoral. Reivindicación 1: Una amatoxina de fórmula (1) donde R¹ se selecciona entre C=O, C=S, C=NR⁶ y CR⁷R⁸ ; R² se selecciona entre S=O, SO₂, y S; R³ se selecciona entre NHR⁵ y OR⁵; R⁴ se selecciona entre H, OR⁵, y O-alquilo C₁₋₆; R⁶ se selecciona entre alquileno C₁₋₆-R⁵, cicloalquileno-R⁵, heterocicloalquileno-R⁵, amileno-R⁵, y heteroarileno-R⁵; R⁷ y R⁸ se seleccionan independientemente entre H, alquileno C₁₋₆-R⁵, cicloalquileno-R⁵, heterocicloalquileno-R⁵, amileno-R⁵, y heteroarileno-R⁵; donde (i) cada R⁵ es H; (ii) uno de R⁵ es -Lₙ-X, donde L es un ligador, n se selecciona entre 0 y 1, y X es un resto químico que puede ser acoplado con un resto que se dirige a la diana, y donde los restantes R⁵ son H; o (iii) uno de R⁵ es -Lₙ-X*-Y, donde L es un ligador, n se selecciona entre 0 y 1, Y es un resto que se dirige hacia la diana, y X* es un resto químico que es el resultado del acoplamiento X con un grupo funcional de Y, y donde los restantes R⁵ son H.
ARP140100717A 2013-03-04 2014-03-05 Derivados de amatoxina AR095019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13001074.7A EP2774624A1 (en) 2013-03-04 2013-03-04 Amatoxin derivatives

Publications (1)

Publication Number Publication Date
AR095019A1 true AR095019A1 (es) 2015-09-16

Family

ID=47826817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100717A AR095019A1 (es) 2013-03-04 2014-03-05 Derivados de amatoxina

Country Status (20)

Country Link
US (1) US9982018B2 (es)
EP (2) EP2774624A1 (es)
KR (1) KR20160006162A (es)
AR (1) AR095019A1 (es)
AU (1) AU2014224928B2 (es)
BR (1) BR112015021838B1 (es)
CA (1) CA2903614C (es)
DK (1) DK2964264T3 (es)
ES (1) ES2652182T3 (es)
HK (1) HK1200312A1 (es)
IL (1) IL240863B (es)
MX (1) MX366503B (es)
NO (1) NO2964264T3 (es)
NZ (1) NZ710729A (es)
RU (1) RU2695370C2 (es)
SG (1) SG11201507089PA (es)
TW (1) TW201441248A (es)
UA (1) UA117364C2 (es)
WO (1) WO2014135282A1 (es)
ZA (1) ZA201505790B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004802A2 (pt) 2014-09-12 2017-12-12 Genentech Inc anticorpos anti-cll-1 e imunoconjugados
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
HRP20201791T1 (hr) * 2015-03-04 2021-04-16 Board Of Regents, The University Of Texas System Postupci za liječenje raka sa hemizigotnim gubitkom gena tp53
MX391989B (es) * 2015-03-09 2025-03-21 Heidelberg Pharma Gmbh Conjugados de amatoxina y anticuerpos.
JP6632118B2 (ja) * 2015-09-04 2020-01-15 学校法人 岩手医科大学 腫瘍の再発を抑制する医薬
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
AU2017204139B2 (en) 2016-06-17 2018-08-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for the depletion of cells
EP3472178A4 (en) 2016-06-17 2020-02-19 Magenta Therapeutics, Inc. COMPOSITION AND METHOD FOR DEPLYING CD117 + CELLS
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7038717B2 (ja) 2016-12-23 2022-03-18 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマニチン抗体コンジュゲート
KR20240161216A (ko) 2017-01-20 2024-11-12 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
JP7335260B2 (ja) * 2017-08-18 2023-08-29 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． 非天然アマニチン類抗体複合物
CA3075218A1 (en) 2017-09-19 2019-03-28 Paul Scherrer Institut Transglutaminase conjugation method and linker
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
AU2018355244B2 (en) 2017-10-24 2025-08-28 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
CA3082310A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
CN111989122A (zh) * 2018-04-13 2020-11-24 海德堡医药研究有限责任公司 用于治疗实体瘤的靶向鹅膏毒素缀合物
JP2021532116A (ja) 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
BR112021021165A2 (pt) 2019-04-24 2022-01-04 Heidelberg Pharma Res Gmbh Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos
US20230173087A1 (en) * 2019-05-23 2023-06-08 Heidelberg Pharma Research Gmbh Antibody drug conjugates with cleavable linkers
KR102092817B1 (ko) * 2019-08-22 2020-03-24 한국화학연구원 아마톡신 유도체 및 이의 제조방법
CN111308100B (zh) * 2020-04-13 2023-04-21 北京维德维康生物技术有限公司 一种检测β-鹅膏毒肽的酶联免疫试剂盒及其制备和应用
KR20230069211A (ko) 2020-09-18 2023-05-18 아라리스 바이오테크 아게 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법
EP4232095A1 (en) 2020-10-25 2023-08-30 Araris Biotech AG Means and methods for producing antibody-linker conjugates
KR20230159480A (ko) * 2021-03-19 2023-11-21 하이델베르크 파마 리서치 게엠베하 B-림프구 특이적 아마톡신 항체 접합체
JP2024539989A (ja) 2021-10-25 2024-10-31 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成する方法
CA3243937A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag PEPTIDE LINKS COMPRISING TWO OR MORE PAYLOADS
WO2024243706A1 (en) * 2023-06-02 2024-12-05 The University Of British Columbia Amatoxin analogs and uses thereof
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
EP2015782A4 (en) * 2006-04-12 2010-04-07 Crosslink Genetics Corp COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
KR20110140124A (ko) 2009-04-08 2011-12-30 하인즈 파울스티히 암치료용 아미톡신-활성 표적 결합 부위
US9233173B2 (en) 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2436398B1 (en) * 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages

Also Published As

Publication number Publication date
NZ710729A (en) 2019-05-31
IL240863B (en) 2019-02-28
CA2903614C (en) 2021-07-06
US20160002298A1 (en) 2016-01-07
SG11201507089PA (en) 2015-10-29
MX366503B (es) 2019-07-11
HK1200312A1 (en) 2015-08-07
ZA201505790B (en) 2017-11-29
MX2015011583A (es) 2016-07-29
EP2774624A1 (en) 2014-09-10
UA117364C2 (uk) 2018-07-25
KR20160006162A (ko) 2016-01-18
WO2014135282A8 (en) 2015-09-17
WO2014135282A1 (en) 2014-09-12
IL240863A0 (en) 2015-10-29
HK1215795A1 (en) 2016-09-15
TW201441248A (zh) 2014-11-01
US9982018B2 (en) 2018-05-29
NO2964264T3 (es) 2018-02-10
BR112015021838B1 (pt) 2021-12-28
RU2015142093A (ru) 2017-04-07
AU2014224928B2 (en) 2017-10-19
AU2014224928A1 (en) 2015-09-10
CA2903614A1 (en) 2014-09-12
ES2652182T3 (es) 2018-01-31
RU2695370C2 (ru) 2019-07-23
DK2964264T3 (en) 2017-12-11
EP2964264B1 (en) 2017-09-13
EP2964264A1 (en) 2016-01-13
BR112015021838A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
AR095019A1 (es) Derivados de amatoxina
MX2022000449A (es) Conjugados peptídicos de citotoxinas como terapéuticos.
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
PE20181953A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CO2019000686A2 (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
CU24385B1 (es) Compuestos éteres de arilo útiles para tratar cancer de célula renal
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
AR110405A1 (es) Compuestos
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
MX2016016288A (es) Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.
AR100006A1 (es) Derivados de tubulisina
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
AR102799A1 (es) Profármacos de agonistas fenólicos de trpv1
AR117206A1 (es) Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
AR101479A1 (es) Derivados de 6-alquinil-piridina
BR112016017781A2 (pt) Compostos de pirazolona e usos dos mesmos
BR112014016635B8 (pt) composto, composição, e, uso de um composto
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112015013350A2 (pt) compostos de triazolona e usos dos mesmos
AR104895A1 (es) Conjugados fluorescentes

Legal Events

Date Code Title Description
FB Suspension of granting procedure